Integra LifeSciences (NASDAQ:IART) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.95 and traded as high as $17.73. Integra LifeSciences shares last traded at $17.56, with a volume of 984,868 shares trading hands.

Wall Street Analyst Weigh In

IART has been the subject of several analyst reports. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and raised their price target for the company from $11.00 to $16.00 in a research note on Thursday, May 28th. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Truist Financial dropped their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Wells Fargo & Company raised their price target on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Four equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $14.00.

Integra LifeSciences Stock Performance

The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The company’s 50-day moving average price is $12.47 and its two-hundred day moving average price is $11.99. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -2.63, a PEG ratio of 1.22 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. The company had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. Integra LifeSciences’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Allianz Asset Management GmbH increased its position in Integra LifeSciences by 88.7% in the 3rd quarter. Allianz Asset Management GmbH now owns 433,738 shares of the life sciences company’s stock valued at $6,215,000 after buying an additional 203,834 shares in the last quarter. SG Americas Securities LLC acquired a new position in Integra LifeSciences during the fourth quarter worth $4,722,000. Assenagon Asset Management S.A. raised its holdings in Integra LifeSciences by 15.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company’s stock worth $6,537,000 after buying an additional 71,950 shares during the last quarter. Tejara Capital Ltd raised its holdings in Integra LifeSciences by 42.6% during the fourth quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after buying an additional 51,300 shares during the last quarter. Finally, Systematic Financial Management LP raised its holdings in Integra LifeSciences by 4.5% during the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock worth $13,769,000 after buying an additional 48,094 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.